Synthesis and in vitro Evaluation of 2-heteroarylidene-1-tetralone Derivatives as Monoamine Oxidase Inhibitors

Abstract

The present study investigates the human monoamine oxidase (MAO) inhibition properties of a series of twelve 2-heteroarylidene-1-tetralone derivatives. Also included are related cyclohexylmethylidene, cyclopentylmethylidene and benzylidene substituted 1-tetralones. These compounds are related to the 2-benzylidene-1-indanone class of compounds which has previously been shown to inhibit the MAOs, with specificity for the MAO-B isoform. The target compounds were synthesised by the Claisen-Schmidt condensation between 7-methoxy-1-tetralone or 1-tetralone, and various aldehydes, under acid (hydrochloric acid) or base (potassium hydroxide) catalysis. The results of the MAO inhibition studies showed that the 2-heteroarylidene-1-tetralone and related derivatives are in most instances more selective inhibitors of the MAO-B isoform compared to MAO-A. (2E)-2-Benzylidene-7-methoxy-3,4-dihydronaphthalen-1(2 H)-one (IC₅₀=0.707 μM) was found to be the most potent MAO-B inhibitor, while the most potent MAO-A inhibitor was (2E)-2-[(2-chloropyridin-3-yl)methylidene]-7-methoxy-3,4-dihydronaphthalen-1(2 H)-one (IC₅₀=1.37 μM). The effect of the heteroaromatic substituent on MAO-B inhibition activity, in decreasing order was found to be: cyclohexyl, phenyl>thiophene>pyridine, furane, pyrrole, cyclopentyl. This study concludes that, although some 2-heteroarylidene-1-tetralone derivatives are good potency MAO inhibitors, in general their inhibition potencies, particularly for MAO-B, are lower than structurally related chalcones and 1-indanone derivatives that were previously studied.

Key words

monoamine oxidase - inhibition - Parkinson’s disease - Alzheimer’s disease - heteroarylidene-1-tetralone - 2-benzylidene-1-tetralone

• References

• 1 Youdim MB, Bakhle Y. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006; 147 Suppl 1: S287-S296
• 2 Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience 2006; 7: 295
• 3 Bach A, Lan NC, Johnson DL. et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proceedings of the National Academy of Sciences 1988; 85: 4934-4938
• 4 Shih J, Chen K, Ridd M. Monoamine oxidase: from genes to behavior. Annual review of neuroscience 1999; 22: 197-217
• 5 Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy: The journal of Human Pharmacology and Drug Therapy 27 (12P2): 2007
• 6 Borroni E, Bohrmann B, Grueninger F. et al. Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease. Journal of Pharmacology and Experimental Therapeutics 2017; 362: 413-423
• 7 Lum CT, Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS spectrums 2012; 17: 107-120
• 8 Da MP, Zürcher G, Wüthrich I. et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of neural transmission. Supplementum 1988; 26: 31-56
• 9 Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. The Journal of Clinical Psychiatry 2012; 73: 17-24
• 10 Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. International review of neurobiology. Elsevier; 2011. pp 169-190
• 11 Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Reviews 2003; 9: 97-140
• 12 Provost JC, Funck-Brentano C, Rovei V. et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clinical Pharmacology & Therapeutics 1992; 52: 384-393
• 13 Bolasco A, Fioravanti R, Carradori S. Recent development of monoamine oxidase inhibitors. Expert Opinion on Therapeutic Patents 2005; 15: 1763-1782
• 14 Gomes MN, Muratov EN, Pereira M. et al. Chalcone derivatives: promising starting points for drug design. Molecules 2017; 22: 1210
• 15 Zhuang C, Zhang W, Sheng C. et al. Chalcone: a privileged structure in medicinal chemistry. Chemical reviews 2017; 117: 7762-7810
• 16 Chimenti F, Fioravanti R, Bolasco A. et al. Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem 2009; 52: 2818-2824
• 17 Robinson SJ, Petzer JP, Petzer A. et al. Selected furanochalcones as inhibitors of monoamine oxidase. Bioorganic & Medicinal Chemistry Letters 2013; 23: 4985-4989
• 18 Minders C, Petzer JP, Petzer A. et al. Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorganic & Medicinal Chemistry Letters 2015; 25: 5270-5276
• 19 Huang L, Lu C, Sun Y. et al. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer’s disease. Journal of Medicinal Chemistry 2012; 55: 8483-8492
• 20 Nel MS, Petzer A, Petzer JP. et al. 2-Heteroarylidene-1-indanone derivatives as inhibitors of monoamine oxidase. Bioorganic chemistry 2016; 69: 20-28
• 21 Nel MS, Petzer A, Petzer JP. et al. 2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase. Bioorganic & Medicinal Chemistry Letters 2016; 26: 4599-4605
• 22 Mostert S, Petzer A, Petzer JP. Indanones As High-Potency Reversible Inhibitors of Monoamine Oxidase. ChemMedChem 2015; 10: 862-873
• 23 Novaroli L, Reist M, Favre E. et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorganic & Medicinal Chemistry 2005; 13: 6212-6217